Vaxira® is a therapeutic vaccine for the treatment of non-small cell lung cancer (NSCLC). It is composed of Racotumomab and aluminum hydroxide adjuvant.


Racotumomab is an anti-idiotypic antibody that mimmics glycolylated gangliosides (NeuGcGM3) in its idiotype.

Overall Survive (ITT)

See overall survival chart in patients treated with Vaxira®

Progression-free survival (PFS)

See progression-free survival graph in patients treated with Vaxira®


Patients Area

What is Vaxira®?

Vaxira® is a biopharmaceutical product that stimulates the body to produce an immune response against lung cancer.

How is Vaxira® administered?

Vaxira® is administered intradermally using a fine needle.

Does it have contraindications?

You should not receive Vaxira® if you are allergic (hypersensitive) to, or have a history of being allergic to any of the chemical or biological compounds in the Vaxira® formulation.

Last Publications


Single-agent maintenance therapy for advanced non-small cell lung cancer (NSCLC): a systematic review and Bayesian network meta-analysis of 26 randomized controlled trials

PeerJ. 2016 Oct 20;4:e2550. eCollection 2016.
Download PDF

A randomized, multicenter, pacebo-controlled clinical trial of Racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients

Clin Cancer Res 2014; 20(14):1-12
Download PDF

Web designed